Machado, Mariana Verdelho (2023) MASLD treatment—a shift in the paradigm is imminent. Frontiers in Medicine, 10. ISSN 2296-858X
![[thumbnail of pubmed-zip/versions/2/package-entries/fmed-10-1316284-r1/fmed-10-1316284.pdf]](http://info.submit4journal.com/style/images/fileicons/text.png)
pubmed-zip/versions/2/package-entries/fmed-10-1316284-r1/fmed-10-1316284.pdf - Published Version
Download (875kB)
Abstract
MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to today, the most effective treatment is weight loss. Weight loss interventions are moving from lifestyle changes to bariatric surgery or endoscopy, and, more recently, to a new wave of anti-obesity drugs that can compete with bariatric surgery. Liver-targeted therapy is a necessity for those patients who already present liver fibrosis. The field is moving fast, and in the near future, we will testify to a disruptive change in MASLD treatment, similar to the paradigm-shift that occurred for hepatitis C almost one decade ago with direct antiviral agents.
Item Type: | Article |
---|---|
Subjects: | Eurolib Press > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 13 Dec 2023 08:42 |
Last Modified: | 13 Dec 2023 08:42 |
URI: | http://info.submit4journal.com/id/eprint/3307 |